H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue
Yahoo Finance·2026-01-19 21:01

Jade Biosciences Inc. (NASDAQ:JBIO) is one of the overlooked growth stocks to buy. On January 7, H.C. Wainwright initiated coverage of Jade Biosciences with a Buy rating and 25pricetarget.Thefirmidentifiedthecompanyasbeingstrategicallypositionedtosecurealeadershiprolewithintheautoimmunemarket.ThefirmprojectsthatJADE101,specificallyforthetreatmentofimmunoglobulinAnephropathy,couldgenerate25 price target. The firm identified the company as being strategically positioned to secure a leadership role within the autoimmune market. The firm projects that JADE101, specifically for the treatment of immunoglobulin A nephropathy, could generate 926 million in risk-adjusted revenue by 2037. In Q3 2025, Jade Biosciences Inc. ( ...